Clinical trials: Cancer, Advanced Solid Tumors
Gastric Cancer, Gastroesophageal Junction Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06921928
- Testing
- AZD4360
- Where
- 14 sites in United States, China and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
The study consisted of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase evaluated the safety, tolerability, and PK of avelumab in combination with M9241 in subjects with locally…
- Trial name
- COMBO (NCT02994953)
- Testing
- Avelumab, M9241, Avelumab (Once weekly)
- Where
- 33 sites in United States, Belgium and 5 more
- Volunteers
- 52 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumors
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of TAB08 when administered intravenously (i.v.) to patients with advanced solid malignancies.
- Trial name
- TAB08 (NCT03006029)
- Testing
- TAB08
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- Theramab LLC
Advanced Solid Tumours
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab).
- Trial name
- NCT02617277
- Testing
- AZD1775, MEDI4736
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Malignant Fungating Wound
Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
This is a first-in-human, single-arm, open-label, dose escalating study to determine the safety and the recommended maximum tolerated dose of the AMT in subjects with malignant cutaneous lesions.
- Trial name
- NCT04807257
- Testing
- Auger Molecular Therapy (AMT)
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- NanoRay Biotech Co., Ltd.
Neoplasms
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally…
- Trial name
- NCT01096030
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 33 people
- Sponsor
- Bayer
Advanced Cancer
Treatment of Carrying TP53 Harmful Mutations
Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.
- Trial name
- NCT03645200
- Testing
- Fluzoparib combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Solid Tumor, Adult, Metastasis
Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care within two previously identified…
- Trial name
- NCT05947695
- Testing
- Palliative and Survivorship Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Good Samaritan Hospital Medical Center, New York
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Tumors
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.
- Trial name
- NCT00201812
- Testing
- Etanercept, Docetaxel, Dexamethasone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00390000
- Testing
- vatalanib, pemetrexed disodium, pharmacological study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Solid Tumors
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to…
- Trial name
- NCT05996445
- Testing
- XmAb662, Keytruda® (pembrolizumab)
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Xencor, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
PR-104 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00349167
- Testing
- PR-104, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Proacta, Incorporated
Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080，or letrozole and trastuzumab, with or without pertuzumab…
- Trial name
- NCT06555068
- Testing
- HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Tumors, Lymphoma
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.
- Trial name
- NCT00345189
- Testing
- CNF2024
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Biogen
Solid Tumors
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a…
- Trial name
- NCT01214668
- Testing
- LY573636-sodium, Liposomal Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.